Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia - Business Wire

Celgene Corporation Announces Key Regulatory Updates for REVLIMID® in Lymphoma and Luspatercept in MDS and Beta-Thalassemia  Business Wire

U.S. FDA grants Priority Review for REVLIMID® (lenalidomide) in combination with rituximab (R²) for previously treated follicular and marginal zone lymphoma.